BNET Industries

Last Fiscal Year Sales:$749.9K
  • Public
  • US
Dow Jones Description

HemoBioTech, Inc. is a biopharmaceutical company developing HemoTech , potentially the first viable substitute for human blood for the broad blood use market. The company's core product HemoTech is a bovine-hemoglobin (Hb) based human blood substitute capable of replacing red blood cells in the human body. HemoBioTech, Inc. has an exclusive worldwide license for HemoTech from Texas Tech University Health Science Center at Lubbock. At HemoBioTech, Inc., our goal is to address an increasing demand for a safe and inexpensive human blood substitute product in the United States and around the world through our licensed technology.

Chairman of the Board of Directors, President and Chief Executive Officer
Arthur P Bollon
Number of Employees 7
Contact Information

5001 Spring Valley Road

Suite 1040 - West

Dallas, Texas 75244

hemobiotech.com

972-455-8950

NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414

News & Analysis

hemobiotech inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Mario Feola Chief Medical Officer
Mark J. Rosenblum Chief Financial Officer
Jan Simoni Acting Vice President, Research and Development An
Lawrence Helson Scientific Advisor
Roscoe M Moore Jr Scientific Advisor
Walter Haeussler Advisor
Bernhard Mittemeyer Director
Robert Baron Director

Board of Directors

Name (plus bio) Position
Arthur P Bollon Chairman of the Board of Directors, President and Chief Executive Officer
Ghassan Nino Co-Founder and Vice Chairman
Robert Comer Chair
Frederick Frank Board of Directors
Robert E. Dragoo Board of Directors

Arthur P. Bollon, Ph.D. - Dr. Bollon brings 25 years experience in biotechnology as a scientist, executive and entrepreneur. He has been the Chairman, President and CEO of HemoBioTech since 2003. - Founder, former Chairman & CEO of Wadley Biosciences Inc., a joint venture between Wadley Cancer Center and Phillips Petroleum. - Founder, former Chairman & CEO of Cytoclonal Pharmaceutics a " led an IPO in 1995 and closed licensing agreement with Bristol Meyers Squibb. - Dr. Bollon holds a Ph.D. in molecular genetics from Rutgers University and was a Post Doctoral Fellow at Yale University.

Organization Position Status
Hemobiotech, Inc. Chairman of the Board of Directors, President and Chief Executive Officer Current
Biogress LLC. Co-Founder Former
Hemobiotech, Inc. Scientist Former
Yale University Fellow Former
University of Texas Health Science Center Assistant Professor Former
Rutgers University Ph.D. In Molecular Genetics Former

Organization Position Status
Hemobiotech, Inc. Chief Medical Officer Current
Texas Tech Professor Current

- Mark Rosenblum joined as the Chief Financial Officer of HemoBioTech on April 1, 2005. - Former Vice President, Chief Accounting Officer & Controller at Wellman, Inc., a $1.2 billion public chemical manufacturer. - Mark Rosenblum holds a master's in accounting and B.S. in accounting from the University of South Carolina. Mr. Rosenblum is also a certified public accountant. Jan Simoni, Ph.D., D.V.M. - Dr. Simoni is the co-inventor of HemoTech and a world-renowned blood substitute scientist. - He is the Acting Vice President of R & D and Advisor at HemoBioTech and Associate Research Professor of Surgery and Internal Medicine at Texas Tech University Health Science Center. - Co-author of over 100 publications, book chapters, and abstracts on human blood substitutes. - Dr. Simoni holds a DVM and a Ph.D. from Wroclaw Agricultural University in Poland.

Organization Position Status
Hemobiotech, Inc. Chief Financial Officer Current
Wellman, Inc. Chief Accounting Officer Former
Wellman, Inc. Vice President Former
Hemobiotech, Inc. Vice President of R & D Former
Wellman, Inc. Controller Former
University of South Carolina B.S. In Accounting Former

Organization Position Status
Hemobiotech, Inc. Acting Vice President, Research and Development An Current
Texas Tech Blood Substitute Group Leader Current

Organization Position Status
Hemobiotech, Inc. Co-Founder and Vice Chairman Current
Pave Systems, Inc Founder Former
Ascend Mobility Founder Former
Biogress LLC. Co-Founder Former
Ascend Director Former

Organization Position Status
Hemobiotech, Inc. Scientific Advisor Current
Meyers Associates L.P Consultant Current

Organization Position Status
Potomac Institute for Policy Studies Senior Fellow Current
Washington Suburban Sanitary Commission Commissioner Current
Hemobiotech, Inc. Scientific Advisor Current
Montgomery Gen Hospital, Inc. Board of Directors Current
The Johns Hopkins University PhD In Epidemiology Former
University of Michigan Master of Public Health In Epidemiology Former

Walter Haeussler, Advisor. Mr. Haeussler, retired from the private practice of law, served as a member of our Board of Directors from March 2004 to January 2008 and currently serves as a member of our Advisory Board. Between August 1998 and August 2002, Mr. Haeussler served as the Director of Technology Transfer at Texas Tech University. Between August 2002 and March 2004, he served as General Counsel to Advisys Inc., an animal biotech company. Between July 1993 and August 1998, Mr. Haeussler served as the President of the Cornell Research Foundation at Cornell University. Between 1972 and 1983, Mr. Haeussler was the Managing Partner of Jones Tallar & Cooper, an intellectual property law firm. Mr. Haeussler serves as a member of the Board of Directors of Thoriun Power, Inc., an alternate energy source company. Mr. Haeussler received his J.D. degree from Duquesne University.

Organization Position Status
Hemobiotech, Inc. Advisor Current
Hemobiotech, Inc. Director Current
Texas Tech University Director of Technology Transfer Former
Duquesne University J.D. Degree Former

Organization Position Status
Hemobiotech, Inc. Chair Current
Hemobiotech, Inc. Director Current

Organization Position Status
Hemobiotech, Inc. Director Current

Organization Position Status
Yale School of Management Advisory Director Current
Landec Corporation Vice Chairman and Director of Lehman Brothers Current
Harvard School of Public Health Advisory Director Current
PureTech Ventures Senior Advisor Current
Salk Institute Director Current
Orbimed Advisors, LLC Chairman of The Board Current
Epix, Inc. Chairman of The Board Current
Predix Pharmaceuticals Holdings, Inc. Chairman of The Board Current
Business Engine, Inc. Director Current
Hemobiotech, Inc. Vice Chairman of Lehman Brothers Current
Egeen Intl. Corp. Vice Chairman Current
Kinemed, Inc Vice Chairman Current
EPIX Pharmaceuticals, Inc. Board of Directors Current
Institute for Systems Biology Director Current
Celtic Pharma Vice Chairman Current
Ophthalmopharma AG. Board of Directors Current
Pharmaceutical Product Development, Inc. Director Current
Diagnostic Products Corporation Director Current
1-800-Doctors, Inc. Director Current
EPIX Pharmaceuticals, Inc. Board of Directors Current
New York Society of Security Analysts Board of Directors Current
PDL BioPharma, Inc. Board of Directors Current
Peter J. Solomon Company Vice Chairman Current
Harvard School of Public Health Advisory Board Member Current
eSoft, Incorporated Director Current
New York Society of Security Analysts Member Current
Smith Barney Vice President Former
Lehman Brothers Holdings Inc. Senior Managing Director Former
Lehman Brothers Holdings Inc. partner Former
Swedish American Life Science Board of Directors Former
Lehman Brothers Holdings Inc. Director Former
Lehman Brothers Holdings Inc. Vice Chairman Former
Barclays Capital Vice Chairman Former
Landec Corporation Board of Directors Former
Stanford University MBA Former
Stanford Graduate School of Business MBA Former
Yale University B.A. Former

Organization Position Status
Nanosensors, Inc. Chairman & Interim CEO Current
Nanosensors, Inc. Director Former
Hemobiotech, Inc. Director Current
Opko Health, Inc. Director Current
Meyers Associates L.P Partner Former
City, Ltd. Chairman Former
Texas Tech University B.S. In Mechanical Engineering Former
The Ohio State University B.S. Degree Former
The Ohio State University Degree In Business Former

Organization Position Status
Hemobiotech, Inc. Board of Directors Current

Executive News

  • Sinapis Pharma Announces Frederick Frank as Consultant

    PR Newswire - 9/08/09 - View Story

  • Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs

    Pharma Live - 8/18/09 - View Story